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Effect of Chronic Glutathione Administration on Striatal 
Dopaminergic Terminals in Intrastriatal 6-Hydroxydopamine-
Treated Rats
Abstract
ࠉMany reports have shown that abnormalities in glutathione are related to the onset of 
Parkinson’s disease. Therefore, the ameliorating effect of glutathione in an animal model of 
Parkinson’s disease was studied. The model was made by injections with 6-hydroxydopamine 
(6-OHDA) into both sides of the striatum. In this model, dopaminergic terminals in the 
striatum gradually regenerate after an initial degeneration. The amount of tyrosine 
hydroxylase, which is a marker of dopaminergic terminals, in the striatum after glutathione 
(100 mg/kg, intraperitoneally) administration twice a week for 8 weeks was compared with 
vehicle-treated 6-OHDA-treated rats. No signiÀcant differences were observed between the two 
groups. Thus, glutathione does not affect dopaminergic terminals. 
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　A small group of physicians have been promoting 
glutathione therapy for Parkinsonian patients and 
charging a fee for infusion of glutathione in their 
office practices in Japan and North America (Okun 
and Lang, 2010). This treatment is based on a 
report by Sechi et al. (1996) in which intravenous 
infusion of glutathione into nine patients with early 
untreated Parkinson’s disease produced a 42% 
decline in disability during the infusions. However, 
in a study that examined 21 patients, intravenous 
administration of glutathione produced no signiÀcant 
improvement (Hauser et al, 2009). 
　Many reports have shown that glutathione 
modulates degeneration of dopaminergic neurons 
in Parkinson’s disease (Smeyne and Smeyne, 2013). 
Therefore, in the present study, an animal model 
of Parkinson’s disease was assessed to investigate 
the beneÀcial effects of glutathione on dopaminergic 
neurons. 
METHODS
　Male 12-week-old Wistar rats (Kyudo Company, 
883-1 Tateishimachi, Tosu, Saga 841-0075, Japan) 
weighing 350-410 g were used. The animals were 
housed with free access to standard food in an air-
conditioned room. All efforts were made to minimize 
animal suffering and to reduce the number of animals 
used. The present experiments were carried out after 
obtaining permission from the Committee of Animal 
Experimentation of Kagoshima Junshin University.
　Pentobarbital (50 mg/kg, intraperitoneally (i.p.) 
was used for anesthesia. To induce degeneration of 
dopaminergic terminals in the striatum, a 12-Ǎg 
dose of 6-hydroxydopamine (6-OHDA) (Sigma, St. 
Louis, MO) dissolved in 3-Ǎl 0.9% saline containing 
0.1% ascorbic acid, was injected into both sides of the 
striatum using a 30-gauge needle at a rate of 1 Ǎl/
min. Desipramine hydrochloride (Sigma, 20 mg/kg) 
dissolved in 40% propyleneglycol containing 10.5% 
ethanol and 0.34 mg/ml NaOH was administered 
i.p. 20 min before the 6-OHDA treatment to preserve 
noradrenergic terminals in the striatum. Using 
a stereotaxic apparatus (Model 900, David Kopf 
Instruments, Pembroke Pines, FL), the tip of the 
needle was inserted vertically through a small hole 
in the skull 0.5 mm rostral and 3.0 mm lateral to 
the bregma and ï5 mm ventral to the brain surface. 
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The needle remained in place for 2 min following the 
infusion to minimize the spread of the drug through 
the injection track.
　Glutathione (Tathion®, Astellas Pharma Inc., 
Tokyo, Japan, 100 mg/kg) was dissolved in distilled 
water and administered i.p. twice a week (every 
Tuesday and Friday) for 8 weeks. Control rats were 
given saline. 
　Rats were decapitated 56 days following 
lesioning, and both sides of the striatum were 
removed onto an ice-cold glass plate using a brain-
cutting block and then sonicated in 500 Ǎl 1% sodium 
dodecylsulfate. The animals were deeply anesthetized 
with ether before they were decapitated. A portion of 
the solution was used for a BCA protein assay (Pierce, 
Rockford, IL). 
　Total protein (5 Ǎg/lane) was separated on a 10% 
polyacrylamide gel. The proteins were transferred 
onto a PVDF membrane (immobilon-P, Millipore Co., 
Billerica, MA) at 30 V for 16 h. The blots were blocked 
in Tris-buffered saline (10 mM Tris, 150 mM NaCl, 
pH 7.4) containing 0.1% Tween 20 and 1% bovine 
serum albumin (blocking buffer) and incubated with 
anti-tyrosine hydroxylase (TH) monoclonal antibody 
(MAB 318, 1:4000, Chemicon International, Inc., 
Temecula, CA) for 1 h. The blot was then incubated 
with anti-mouse IgG horseradish peroxidase (A5278, 
1:40,000, Sigma) for 30 min. Immunoreactivity on the 
blot was visualized with enhanced chemiluminescence 
(ECL) techniques (ECL Plus, Amersham Co., 
Arlington Heights, IL). Image analysis was performed 
by Image-J (Abramoff et al, 2004).
RESULTS
　The densities of the TH bands (average ± 
standard error (number of striata)) in glutathione-
administered rats and in control rats were 228 ± 10 
(6) and 215 ± 10 (5), respectively (Fig.). The difference 
was not statistically signiÀcant (Student’s t-test, p = 
0.41). 
DISCUSSION
　The present result  shows that chronic 
administration of glutathione had no effect on the 
amount of TH in rats treated with 6-OHDA. 
　We used a striatal 6-OHDA injection rat 
model in the experiments. This model is suitable 
for investigating degeneration and regeneration 
of dopaminergic neurons, because dopaminergic 
terminals gradually degenerate, allowing researchers 
to assess the effect of drugs (Blandini et al, 2008). It 
was previously shown that dopaminergic terminals 
are gradually restored with this model (Iwata et al, 
2001).
　Two experimental protocols can be used in 
6-OHDA animal models to identify a substance with 
a beneficial effect on nigrostriatal dopaminergic 
neurons. In one protocol, the substance is pretreated 
before 6-OHDA injection. In the other, the substance 
is administered after 6-OHDA. Pretreatment with a 
substance implies protection of dopaminergic neurons 
from the toxic effect of 6-OHDA. Many substances are 
protective against this toxicity (Santos, 2012). The 
pretreatment regimen is not suitable for identifying 
a substance that preserves dopaminergic neurons in 
Parkinson’s disease for two reasons. The Àrst is that 
a longitudinal prospective cohort positron emission 
tomography study showed that dopaminergic 
neurons die faster in the early phase of Parkinson’s 
disease, i.e., 5-6 years before disease onset (Hilker 
et al, 2005), when parkinsonian symptoms are not 
apparent. Therefore, a substance considered to be 
protective should be taken at least 5-6 years before 
disease onset. As we are currently unable to predict 
who will develop Parkinson’s disease, such protective 
measures are inappropriate. The second rationale is 
that, in the 6-OHDA striatal model, dopaminergic 
terminals in the striatum initially degenerate due to 
the direct effect of 6-OHDA. Then, the dopaminergic 
neuronal soma with severally damaged terminals due 
to the direct effect of 6-OHDA gradually degenerate 
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(retrograde degeneration). Subsequently, the 
terminals that survived the direct effect of 6-OHDA 
begin to degenerate due to the degeneration of the 
dopaminergic soma (anterograde degeneration; 
Wallerian degeneration). This implies that successive 
degeneration of dopaminergic neurons cannot be 
inhibited by a substance that blocks the direct toxic 
effect of 6-OHDA. Therefore, the post-treatment 
regimen in 6-OHDA animal studies is more suitable 
than pre-treatment for identifying disease-modifying 
substances. 
　Several substances show a protective effect 
on dopaminergic neurons after administration of 
6-OHDA, including calcitriol (Smith et al, 2006), 
melatonin (Ozsoy et al, 2015), hesperidin (Antunes 
et al, 2014), Àbroblast growth factor (Sleeman et al, 
2012), and hydrogen water (Ito et al, 2012). 
　In the present study, glutathione failed to 
regenerate dopaminergic terminals in the striatum, 
as shown by the absence of an increase in TH. 
Glutathione should not be used in Parkinsonian 
patients as both an animal and a human study 
showed no effect on Parkinson’s disease. 
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